Skip to main content

Articles

Page 31 of 32

  1. Ovarian cancer is sixth most common cancer among women and the leading cause of death in women with gynecological malignancies. Despite the great impact ovarian cancer has on women's health and its great impac...

    Authors: Marcela F Paes, Renata D Daltoé, Klesia P Madeira, Lucas CD Rezende, Gabriela M Sirtoli, Alice L Herlinger, Leticia S Souza, Luciana B Coitinho, Débora Silva, Murilo F Cerri, Ana Cristina N Chiaradia, Alex A Carvalho, Ian V Silva and Leticia BA Rangel
    Citation: Journal of Ovarian Research 2011 4:14
  2. Study of the hen immune system led to seminal contributions to basic immunological principles. Recent studies of spontaneous ovarian cancer in the laying hen show strikingly similar tumor types and antigen exp...

    Authors: Yi Yu, Seby L Edassery, Animesh Barua, Jacques S Abramowicz, Janice M Bahr, Ingegerd Hellstrom and Judith L Luborsky
    Citation: Journal of Ovarian Research 2011 4:12
  3. Endometriosis Health Profile (EHP-5) is a valid instrument to measure health-related quality of life in endometriosis. This study was conducted to culturally adapt and validate the EHP-5 in Iran.

    Authors: Azita Goshtasebi, Maryam Nematollahzadeh, Fatemeh Zahra Hariri and Ali Montazeri
    Citation: Journal of Ovarian Research 2011 4:11
  4. Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer death in the USA. Recurrence rates are high after front-line therapy and most patients eventually die from platinum (Pt) - resistant d...

    Authors: Clarisse S Muenyi, Vanessa A States, Joshua H Masters, Teresa W Fan, C William Helm and J Christopher States
    Citation: Journal of Ovarian Research 2011 4:9
  5. Metformin, an oral biguanide traditionally used for the treatment of type 2 diabetes, is widely used for the management of polycystic ovary syndrome (PCOS)-related anovulation. Because of the significant preva...

    Authors: Mary E Sabatini, Lankai Guo, Maureen P Lynch, Joseph O Doyle, HoJoon Lee, Bo R Rueda and Aaron K Styer
    Citation: Journal of Ovarian Research 2011 4:8
  6. Recent evidence has suggested that the capability of cancer to grow, propagate and relapse after therapy is dependent on a small subset of the cell population within the tumor, called cancer stem cells. Theref...

    Authors: Moorthy P Ponnusamy, Parthasarathy Seshacharyulu, ArokiaPriyanka Vaz, Parama Dey and Surinder K Batra
    Citation: Journal of Ovarian Research 2011 4:7
  7. In the search for unique ovarian cancer biomarkers, ovarian specific cDNA microarray analysis identified hRad17, a cell cycle checkpoint protein, as over-expressed in ovarian cancer. The aim of this study was ...

    Authors: Jennifer L Young, E Colin Koon, Joseph Kwong, William R Welch, Michael G Muto, Ross S Berkowitz and Samuel C Mok
    Citation: Journal of Ovarian Research 2011 4:6
  8. Malignant transformation is a rare complication of mature cystic teratoma with squamous cell carcinoma being the most common type. We report a new case of squamous cell carcinoma in situ.

    Authors: Fatima A Zakkouri, Saloua Ouaouch, Saber Boutayeb, Mouna Rimani, Lamiae Gamra, Hind Mrabti and Hassan Errihani
    Citation: Journal of Ovarian Research 2011 4:5
  9. Sphingosine-1 receptor 1 (S1P1) plays a major role in regulating lymphocyte egress from peripheral lymph tissue. Lymphocyte trafficking is potentially a critical response to tumors and to tumor vaccines. Also,...

    Authors: Michael J Bradaric, Animesh Barua, Krishna Penumatsa, Yu Yi, Seby L Edassery, Sameer Sharma, Jacques S Abramowicz, Janice M Bahr and Judith L Luborsky
    Citation: Journal of Ovarian Research 2011 4:4
  10. The prostaglandin D2 (PGD2) pathway is involved in numerous biological processes and while it has been identified as a partner of the embryonic sex determining male cascade, the roles it plays in ovarian funct...

    Authors: Andalib Farhat, Pascal Philibert, Charles Sultan, Francis Poulat and Brigitte Boizet-Bonhoure
    Citation: Journal of Ovarian Research 2011 4:3
  11. Blood flow in the corpus luteum (CL) is closely related to luteal function. It is unclear how luteal blood flow is regulated. Standardized ovarian-stimulation protocol with a gonadotropin-releasing hormone ago...

    Authors: Akihisa Takasaki, Isao Tamura, Fumie Kizuka, Lifa Lee, Ryo Maekawa, Hiromi Asada, Toshiaki Taketani, Hiroshi Tamura, Katsunori Shimamura, Hitoshi Morioka and Norihiro Sugino
    Citation: Journal of Ovarian Research 2011 4:2
  12. We showed there are specific ALDH1 autoantibodies in ovarian autoimmune disease and ovarian cancer, suggesting a role for ALDH1 in ovarian pathology. However, there is little information on the ovarian express...

    Authors: Krishna Penumatsa, Seby L Edassery, Animesh Barua, Michael J Bradaric and Judith L Luborsky
    Citation: Journal of Ovarian Research 2010 3:28
  13. Ovarian cancer is the second most common cancer among women and the leading cause of death among gynecologic malignancies. In recent years, infrared (IR) spectroscopy has gained attention as a simple and inexp...

    Authors: Ranjana Mehrotra, Gunjan Tyagi, Deepak K Jangir, Ramesh Dawar and Noopur Gupta
    Citation: Journal of Ovarian Research 2010 3:27
  14. To verify the feasibility of ovarian stromal evaluation and correlate ovarian parameteres (echogenicity and volume) with hyperandrogenism, and both cardiovascular and metabolic risk factors in PCOS.

    Authors: Giuseppe Loverro, Giovanni De Pergola, Edoardo Di Naro, Massimo Tartagni, Cristina Lavopa and Anna Maria Caringella
    Citation: Journal of Ovarian Research 2010 3:25
  15. Most cases of ovarian cancer are epithelial in origin and diagnosed at advanced stage when the cancer is widely disseminated in the peritoneal cavity. The objective of this study was to establish an immunocomp...

    Authors: Bridget A Quinn, Fang Xiao, Laura Bickel, Lainie Martin, Xiang Hua, Andres Klein-Szanto and Denise C Connolly
    Citation: Journal of Ovarian Research 2010 3:24
  16. Given the high rate of pregnancy and perinatal complications recently observed in patients with polycystic ovary syndrome (PCOS) and the lack of data on the serum variations in androgens and insulin sensitivit...

    Authors: Angela Falbo, Morena Rocca, Tiziana Russo, Antonietta D'Ettore, Achille Tolino, Fulvio Zullo, Francesco Orio and Stefano Palomba
    Citation: Journal of Ovarian Research 2010 3:23
  17. New biomarkers that replace or are used in conjunction with the current ovarian cancer diagnostic antigen, CA125, are needed for detection of ovarian cancer in the presurgical setting, as well as for detection...

    Authors: John D Andersen, Kristin LM Boylan, Ronald Jemmerson, Melissa A Geller, Benjamin Misemer, Katherine M Harrington, Starchild Weivoda, Bruce A Witthuhn, Peter Argenta, Rachel Isaksson Vogel and Amy PN Skubitz
    Citation: Journal of Ovarian Research 2010 3:21
  18. chA21 is a novel tumor-inhibitory antibody which recognized subdomain I of HER2 extracellular domain with an epitope distinct from other HER2 antibodies. Previously, we demonstrated that chA21 inhibits human o...

    Authors: Anli Zhang, Guodong Shen, Ting Zhao, Guihong Zhang, Jing Liu, Lihua Song, Wei Wei, Ling Bing, Zhengsheng Wu and Qiang Wu
    Citation: Journal of Ovarian Research 2010 3:20
  19. This review describes the use of polymer micelle nanotechnology based chemotherapies for ovarian cancer. While various chemotherapeutic agents can be utilized to improve the survival rate of patients with ovar...

    Authors: Murali M Yallapu, Meena Jaggi and Subhash C Chauhan
    Citation: Journal of Ovarian Research 2010 3:19
  20. The association of pseudo-Meigs' syndrome, elevation of CA 125 to the struma ovarii is a rare condition. So far only nine cases have been reported in English literature through MEDLINE search. Here we report a...

    Authors: Wei Jiang, Xin Lu, Zhi Ling Zhu, Xi Shi Liu and Cong Jian Xu
    Citation: Journal of Ovarian Research 2010 3:18
  21. In view of the recent association of Brn-3 transcription factors with neuroblastomas, cervical, breast, and prostate cancers we examined the expression of Brn-3a(l) in normal ovaries and in different histologi...

    Authors: Nuzhat Ahmed, Ardian Latifi, Clyde B Riley, Jock K Findlay and Michael A Quinn
    Citation: Journal of Ovarian Research 2010 3:17
  22. No data regarding metformin effects on follicular fluid anti-Müllerian hormone (AMH) levels were to date available in literature. The aim of the present study was to evaluate in patients with polycystic ovary ...

    Authors: Angela Falbo, Morena Rocca, Tiziana Russo, Antonietta D'Ettore, Achille Tolino, Fulvio Zullo, Francesco Orio and Stefano Palomba
    Citation: Journal of Ovarian Research 2010 3:16
  23. Cisplatin is more often used to treat ovarian cancer (OvCa), which provides modest survival advantage primarily due to chemo-resistance and up regulated anti-apoptotic machineries in OvCa cells. Therefore, tar...

    Authors: Erica L Johnson, Rajesh Singh, Crystal M Johnson-Holiday, William E Grizzle, Edward E Partridge, James W Lillard Jr and Shailesh Singh
    Citation: Journal of Ovarian Research 2010 3:15
  24. Altered androgen hormone homeostasis and androgen receptor (AR) activity have been implicated in ovarian carcinogenesis but the relationship between AR expression in ovarian cancer and clinical outcome remains...

    Authors: Björn Nodin, Nooreldin Zendehrokh, Jenny Brändstedt, Elise Nilsson, Jonas Manjer, Donal J Brennan and Karin Jirström
    Citation: Journal of Ovarian Research 2010 3:14
  25. Mesenchymal Progenitor/Stem Cells (MSC) respond to homing cues providing an important mechanism to deliver therapeutics to sites of injury and tumors. This property has been confirmed by many investigators, ho...

    Authors: Svetlana Komarova, Justin Roth, Ronald Alvarez, David T Curiel and Larisa Pereboeva
    Citation: Journal of Ovarian Research 2010 3:12
  26. Chemo/radio-resistance is a major obstacle in treating advanced ovarian cancer. The efficacy of current treatments may be improved by increasing the sensitivity of cancer cells to chemo/radiation therapies. Cu...

    Authors: Murali M Yallapu, Diane M Maher, Vasudha Sundram, Maria C Bell, Meena Jaggi and Subhash C Chauhan
    Citation: Journal of Ovarian Research 2010 3:11
  27. Noscapine, an alkaloid from Papaver somniferum, widely used as an antitussive, is being clinically studied in the treatment of polycystic ovary syndrome (PCOS) and a few other cancers primarily because of its ant...

    Authors: Anjali Priyadarshani, Krishna Chuttani, Gaurav Mittal and Aseem Bhatnagar
    Citation: Journal of Ovarian Research 2010 3:10
  28. Ovarian carcinoma is the fourth most common cause of death from cancer in women. Limited progress has been made toward improving the survival rate of patients with this disease in part because of the lack of a...

    Authors: Allison C Sharrow, Brigitte M Ronnett, Christopher J Thoburn, James P Barber, Robert L Giuntoli II, Deborah K Armstrong, Richard J Jones and Allan D Hess
    Citation: Journal of Ovarian Research 2010 3:9
  29. Ovarian cancer is particularly insidious in nature. Its ability to go undetected until late stages coupled with its non-descript signs and symptoms make it the seventh leading cause of cancer related deaths in...

    Authors: Jennifer AA Gubbels, Nick Claussen, Arvinder K Kapur, Joseph P Connor and Manish S Patankar
    Citation: Journal of Ovarian Research 2010 3:8
  30. Ovarian follicle development is a complex process. Paracrine interactions between somatic and germ cells are critical for normal follicular development and oocyte maturation. Studies have suggested that the he...

    Authors: Jin-Yi Jiang, Huiling Xiong, Mingju Cao, Xuhua Xia, Marc-Andre Sirard and Benjamin K Tsang
    Citation: Journal of Ovarian Research 2010 3:6
  31. Activation of bone morphogenetic protein (BMP)4 signalling in human ovarian cancer cells induces a number of phenotypic changes in vitro, including altered cell morphology, adhesion, motility and invasion, relati...

    Authors: Trevor G Shepherd, Michelle L Mujoomdar and Mark W Nachtigal
    Citation: Journal of Ovarian Research 2010 3:5
  32. The Foxl2 transcription factor is required for ovarian function during follicular development. The mechanism of Foxl2 regulation of this process has not been elucidated. Our approach to begin to understand Fox...

    Authors: Jean M Escudero, Jodi L Haller, Colin M Clay and Kenneth W Escudero
    Citation: Journal of Ovarian Research 2010 3:4
  33. Endometrioid carcinoma of the ovary is one of the most types of epithelial ovarian cancer associated to endometrioisis. Endometrioid tumors as well as endometriotic implants are characterized by the presence o...

    Authors: Mamadou Keita, Paul Bessette, Manuella Pelmus, Youssef Ainmelk and Aziz Aris
    Citation: Journal of Ovarian Research 2010 3:3
  34. The production of ascites is a common complication of ovarian cancer. Ascites constitute a unique tumor microenvironment that may affect disease progression. In this context, we recently showed that ovarian ca...

    Authors: Denis Lane, Isabelle Matte, Claudine Rancourt and Alain Piché
    Citation: Journal of Ovarian Research 2010 3:1
  35. Ovarian cancer is the most lethal gynecologic malignancy and the five-year survival rate is only 35% after diagnosis. Epithelial ovarian cancer is a highly metastatic disease characterized by widespread perito...

    Authors: Subhash C Chauhan, Deepak Kumar and Meena Jaggi
    Citation: Journal of Ovarian Research 2009 2:21
  36. During ovulation, it has been shown that LH stimulus induces the expression of numerous genes via PKA, p38 MAPK, PI3K and ERK1/2 in cumulus cells and granulosa cells. Our recent study showed that EGF-like fact...

    Authors: Yasuhisa Yamashita, Mitsugu Hishinuma and Masayuki Shimada
    Citation: Journal of Ovarian Research 2009 2:20
  37. Tumours with high proportions of differentiated cells are considered to be of a lower grade to those containing high proportions of undifferentiated cells. This property may be linked to the differentiation pr...

    Authors: Michael F Gallagher, Richard J Flavin, Salah A Elbaruni, Jamie K McInerney, Paul C Smyth, Yvonne M Salley, Sebastian F Vencken, Sharon A O'Toole, Alexandros Laios, Mathia YC Lee, Karen Denning, Jinghuan Li, Sinead T Aherne, Kai Q Lao, Cara M Martin, Orla M Sheils…
    Citation: Journal of Ovarian Research 2009 2:19
  38. Theca cells play an important role in controlling ovarian steroidogenesis by providing aromatizable androgens for granulosa cell estrogen biosynthesis. Although it is well established that the steroidogenic ac...

    Authors: Shin Fukuda, Makoto Orisaka, Kimihisa Tajima, Katsushige Hattori and Fumikazu Kotsuji
    Citation: Journal of Ovarian Research 2009 2:17
  39. Ovarian cancer is the most lethal gynecologic malignancy. The ovarian tumor microenvironment is comprised of tumor cells, surrounding stroma, and circulating lymphocytes, an important component of the immune r...

    Authors: Nicole S Anderson, Leslie Turner, Sandra Livingston, Ren Chen, Santo V Nicosia and Patricia A Kruk
    Citation: Journal of Ovarian Research 2009 2:16
  40. Overexpression of STYK1, a putative serine/threonine and tyrosine receptor protein kinase has been shown to confer tumorigenicity and metastatic potential to normal cells injected into nude mice. Mutation of a ty...

    Authors: Kesmic A Jackson, Gabriela Oprea, Jeffrey Handy and K Sean Kimbro
    Citation: Journal of Ovarian Research 2009 2:15
  41. Ovarian epithelial tumors are an hallmark of hereditary cancer syndromes which are related to the germ-line inheritance of cancer predisposing mutations in BRCA1 and BRCA2 genes. Although these genes have been...

    Authors: Pierosandro Tagliaferri, Monica Ventura, Francesco Baudi, Iole Cucinotto, Mariamena Arbitrio, Maria Teresa Di Martino and Pierfrancesco Tassone
    Citation: Journal of Ovarian Research 2009 2:14

Annual Journal Metrics

  • 2022 Citation Impact
    4.0 - 2-year Impact Factor
    4.7 - 5-year Impact Factor
    1.118 - SNIP (Source Normalized Impact per Paper)
    0.965 - SJR (SCImago Journal Rank)

    2022 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    149 days submission to accept (Median)

    2022 Usage 
    948,355 downloads
    744 Altmetric mentions 

New Content ItemEditor-in-Chief Dr Sham Kakar has been recognised as being among the top 2% most-cited researchers in the world. Please join us in celebrating this amazing achievement. 

Read more here.